Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents

Main Article Content

ZP Rice
Dermatology Associates of Georgia, Atlanta, GA

LJ Pieretti
International Hyperhidrosis Society, Center Valley, PA

A Wheeler
Cello Health Insight, New York, NY

J Payne
Cello Health Insight, New York, NY

KK Gillard
Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, Menlo Park, CA

AA Hebert
UTHealth McGovern Medical School, Houston, TX

Keywords

Hyperhidrosis, Pediatrics, Adolescents, Quality of Life

Abstract

Abstract not available.

References

1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743-749.

2. Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis (PFHh) among teens 12-17 in US Population. Oral (Late-
Breaker) presented at 75th Annual Meeting of the American Academy of Dermatology; 2017; Orlando, FL.

3. Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10-13.

4. Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: Evidence of genetic transmission. Journal of Vascular Surgery. 2002;35(2):382-386.

5. Wadhawa S, Agrawal S, Chaudhary M, Sharma S. Hyperhidrosis Prevalence: A Disease Underreported by Patients and Underdiagnosed by Physicians. Indian Dermatol Online J.
2019;10(6):676-681.

6. Gelbard CM, Epstein H, Hebert A. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatr Dermatol. 2008;25(6):591-598.

7. Shalaby M, Abd El Hay S. Hyperhidrosis in children and review of its current

8. evidence-based management. Ann Pediatr Surg 2015;11:169-172.

9. Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience With Hyperhidrosis: A National Survey of 1,985 Patients. J Drugs Dermatol. 2018;17(4):392-396.

10. Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):217-222.

11. Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin. 2014;32(4):467-476.

12. Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients’ daily life and quality of life: a qualitative investigation. Health Qual Life
Outcomes. 2017;15(1):121.

13. Glaser DA, Hebert AA, Pariser DM, Solish N. Primary focal hyperhidrosis: scope of the problem. Cutis. 2007;79(5 Suppl):5-17.

14. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274-286.

15. Bohaty BR, Hebert AA. Special considerations for children with hyperhidrosis. Dermatol Clin. 2014;32(4):477-484.

16. IHhs. HyperhidrosisTreatment Algorithms https://www.sweathelp.org/treatments-hcp/clinical-guidelines/hyperhidrosis-treatment-algorithms.html. Updated September 23 2018.
Accessed June 3, 2019.

17. IHhs. Treatment Overview https://www.sweathelp.org/treatments-hcp/treatment-overview.html. Accessed June 3, 2019.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.117

Article Details

How to Cite
[1]
Rice, Z., Pieretti, L., Wheeler, A., Payne, J., Gillard, K. and Hebert, A. 2020. Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s117. DOI:https://doi.org/10.25251/skin.4.supp.117.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Hyperhidrosis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.